BeyondSpring's Next Move Uncertain After Plinabulin CRL

Limited Impact On China Partner Hengrui?

 
• By Brian Yang

Chinese firm BeyondSpring dealt a setback after the US FDA refuses to approve plinabulin for chemotherapy-induced neutropenia.

Business uncertainty and risk showing a winding road high above the clouds showing the concept of danger and challenges faced in business and the corporate world of finance and financial services.
BEYONDSPRING'S PLINABULIN GETS US CRL, NEXT MOVE UNCERTAIN • Source: Alamy

More from New Products

More from Scrip